Pacira BioSciences Inc PCRX
News
Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
Pacira BioSciences Reports Second Quarter 2024 Financial Results
Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024
Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
Pacira BioSciences Shares Tumble as FDA Approves Exparel Generic
Pacira's PCRX-201 Gets FDA RMAT Designation in Knee Osteoarthritis